Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Magnolia Flower Nasal Spray is a traditional Chinese medicine (TCM) botanical product developed by Guizhou Bailing Group Pharmaceutical for the treatment of acute rhinitis, specifically the 'wind-cold' pattern. The formulation is centered on the therapeutic properties of Flos Magnoliae (Xin Yi), which is traditionally used in TCM to relieve nasal congestion and sinus pressure. As a compound nasal spray, it likely incorporates multiple herbal extracts to provide localized anti-inflammatory and decongestant effects. The drug has been evaluated in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in China to determine its efficacy, safety, and optimal dosage for patients suffering from acute rhinitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound magnolia flower nasal spray.